We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Novartis Ireland Limited

Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, Ireland
Telephone: +353 1 2601255
Fax: +353 1 2601263
Medical Information e-mail: medinfo.dublin@novartis.com
Patient Information Leaflet last updated on medicines.ie: 13/09/2017
PIL Atriance 5 mg/ml solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13/09/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - what the product contains
Updated on 25/05/2016 and displayed until 13/09/2017
Reasons for adding or updating:
  • Change to marketing authorisation holder
Updated on 30/08/2013 and displayed until 25/05/2016
Reasons for adding or updating:
  • Change to side-effects
Updated on 16/05/2013 and displayed until 30/08/2013
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 07/11/2012 and displayed until 16/05/2013
Reasons for adding or updating:
  • Change to dosage and administration
Updated on 27/03/2012 and displayed until 07/11/2012
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 28/04/2011 and displayed until 27/03/2012
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 05/10/2007 and displayed until 28/04/2011
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Nelarabine